Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States and Europe. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Madrigal Therapeutics are building a global team to launch their first asset for NASH/MASH. Morgan Prestwich were retained to build their UK affiliate team. We successfully delivered the following positions:

UK affiliate build to date:
- General Manager
- Medical Director
- Market Access Director
- Commercial Director
- 3 x MSL's